Colorectal cancer (CRC) remains a leading cause of cancer-related morbidity and mortality worldwide, with many cases still diagnosed at advanced stages despite being largely preventable through early screening. Conventional screening approaches, such as colonoscopy and fecal occult blood testing, are effective but limited by invasiveness, low compliance, and suboptimal sensitivity for early-stage disease, underscoring the need for more precise and acceptable alternatives. Recent advances in molecular diagnostics have enabled the detection of cancer-associated genetic and epigenetic alterations, including mutations in APC, KRAS, BRAF, and TP53, as well as microsatellite instability and aberrant DNA methylation, which may be detectable years before clinical manifestation of disease. Emerging technologies such as liquid biopsy and multitarget stool DNA testing are transforming CRC screening by providing minimally invasive approaches with improved diagnostic performance. These advances are further supported by next-generation sequencing, multiplex polymerase chain reaction, artificial intelligence, and machine learning, which enable the identification of complex biomarker patterns that were previously inaccessible. Several molecular assays have already received regulatory approval and show strong clinical utility, particularly in populations less likely to undergo invasive procedures. However, important challenges persist, including false-positive and false-negative results, high cost, lack of standardization, and ethical concerns related to data privacy, particularly in resource-limited settings. As the field advances toward precision prevention, integrating individualized risk profiling with molecular screening strategies may improve diagnostic accuracy and patient outcomes. Ultimately, the success of molecular CRC screening will depend not only on technological innovation but also on ensuring equitable access, affordability, and patient trust. In this perspective, we highlight the molecular revolution in CRC screening, emphasizing how modern technologies have enhanced the speed, accuracy, and uptake of screening strategies. While traditional methods are hindered by limited patient compliance and diagnostic performance, the integration of advanced molecular diagnostics (including liquid biopsies and multitarget DNA testing) is reshaping early detection. Nevertheless, the full potential of this “molecular revolution” will only be realized by addressing barriers related to cost, standardization, and global health equity.